Several groups are currently developing methods to detect somatic mutations with the aim of discovering markedly higher cell-free DNA (cfDNA) concentrations in the blood of patients with cancer, in particular, KRAS from plasma and serum8–11. The gene discussed is KRAS; the disease is cancer.